- Home
- WATT vs APM Comparison
WATT vs APM Comparison
Compare WATT & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- APM
- Stock Information
- Founded
- WATT 2012
- APM 2010
- Country
- WATT United States
- APM United Kingdom
- Employees
- WATT N/A
- APM N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- APM Health Care
- Exchange
- WATT Nasdaq
- APM Nasdaq
- Market Cap
- WATT 3.9M
- APM 4.1M
- IPO Year
- WATT 2014
- APM 2018
- Fundamental
- Price
- WATT $0.30
- APM $0.73
- Analyst Decision
- WATT Strong Buy
- APM
- Analyst Count
- WATT 2
- APM 0
- Target Price
- WATT $2.25
- APM N/A
- AVG Volume (30 Days)
- WATT 350.0K
- APM 46.3K
- Earning Date
- WATT 11-12-2024
- APM 01-03-2025
- Dividend Yield
- WATT N/A
- APM N/A
- EPS Growth
- WATT N/A
- APM N/A
- EPS
- WATT N/A
- APM 0.00
- Revenue
- WATT $431,184.00
- APM N/A
- Revenue This Year
- WATT $95.75
- APM $157,729.10
- Revenue Next Year
- WATT $834.07
- APM N/A
- P/E Ratio
- WATT N/A
- APM $208.83
- Revenue Growth
- WATT N/A
- APM N/A
- 52 Week Low
- WATT $0.28
- APM $0.46
- 52 Week High
- WATT $2.75
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- WATT 21.40
- APM 37.75
- Support Level
- WATT $0.28
- APM $0.67
- Resistance Level
- WATT $0.34
- APM $0.77
- Average True Range (ATR)
- WATT 0.04
- APM 0.07
- MACD
- WATT -0.00
- APM 0.03
- Stochastic Oscillator
- WATT 7.55
- APM 29.04
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.